179 related articles for article (PubMed ID: 18217998)
1. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
[TBL] [Abstract][Full Text] [Related]
2. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
[TBL] [Abstract][Full Text] [Related]
6. [Lipid profile of atazanavir].
Martínez Chamorro E
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():34-40. PubMed ID: 20116615
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
8. Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Grover SA; Coupal L; Gilmore N; Mukherjee J
Am J Cardiol; 2005 Mar; 95(5):586-91. PubMed ID: 15721096
[TBL] [Abstract][Full Text] [Related]
9. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
[TBL] [Abstract][Full Text] [Related]
10. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
[TBL] [Abstract][Full Text] [Related]
11. Case presentation: nephrolithiasis in a patient treated with atazanavir.
Savini C; James C; Wilson S; Martin H; Szabo S; Scotto V
J Assoc Nurses AIDS Care; 2008; 19(3):225-7. PubMed ID: 18457764
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences.
Neumann T; Woiwod T; Neumann A; Ross B; Von Birgelen C; Volbracht L; Brockmeyer NH; Gerken G; Erbel R
Eur J Med Res; 2004 Feb; 9(2):55-60. PubMed ID: 15090290
[TBL] [Abstract][Full Text] [Related]
13. Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
de Saint-Martin L; Bressollette L; Perfezou P; Bellein V; Ansart S; Vallet S; Pasquier E
AIDS; 2010 Nov; 24(18):2797-801. PubMed ID: 21063175
[TBL] [Abstract][Full Text] [Related]
14. Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
Murphy RL; Berzins B; Zala C; Fichtenbaum C; Dube MP; Guaraldi G; Torriani F; Belsey E; Mitchell C; Stein JH;
AIDS; 2010 Mar; 24(6):885-90. PubMed ID: 19952712
[TBL] [Abstract][Full Text] [Related]
15. Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult.
Jacques AC; Giguère P; Zhang G; Touchie C; la Porte CJ
Ann Pharmacother; 2010 Jan; 44(1):202-6. PubMed ID: 19955297
[TBL] [Abstract][Full Text] [Related]
16. Atazanavir urolithiasis.
Chang HR; Pella PM
N Engl J Med; 2006 Nov; 355(20):2158-9. PubMed ID: 17108352
[No Abstract] [Full Text] [Related]
17. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial.
Flammer AJ; Vo NT; Ledergerber B; Hermann F; Gämperli A; Huttner A; Evison J; Baumgartner I; Cavassini M; Hayoz D; Quitzau K; Hersberger M; Sudano I; Ruschitzka F; Lüscher TF; Noll G; Weber R
Heart; 2009 Mar; 95(5):385-90. PubMed ID: 18653575
[TBL] [Abstract][Full Text] [Related]
18. Does atazanavir cause lipodystrophy?
Gazzard BG; Moyle G
J HIV Ther; 2004 May; 9(2):41-4. PubMed ID: 15238875
[TBL] [Abstract][Full Text] [Related]
19. Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects.
Guffanti M; Caumo A; Galli L; Bigoloni A; Galli A; Dagba G; Danise A; Luzi L; Lazzarin A; Castagna A
Eur J Endocrinol; 2007 Apr; 156(4):503-9. PubMed ID: 17389467
[TBL] [Abstract][Full Text] [Related]
20. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
Iloeje UH; Yuan Y; L'italien G; Mauskopf J; Holmberg SD; Moorman AC; Wood KC; Moore RD
HIV Med; 2005 Jan; 6(1):37-44. PubMed ID: 15670251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
